Laboratory Aktie News

Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leade...

Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research BURLINGTON, N.C. , Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tu...

DURHAM, N.C. and SEOUL, South Korea , Nov. 17, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation in digital pathology (DP) and artificial intelligence (AI) for oncology research and clinical care.

Labcorp Holdings Inc. (NYSE:LH ) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Christin O'Donnell - Vice President of Investor Relations Adam Schechter - President, CEO & Chairman Julia Wang - CFO & Executive VP Conference Call Participants Lisa Gill - JPMorgan Chase & Co, Research Division Michael Cherny - Leerink Partners LLC, Research Division Jack Meehan - Nephron ...

Labcorp on Tuesday raised its annual profit forecast and beat estimates in the third quarter as the laboratory operator benefited from strong demand for its diagnostic tests.

Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion Diluted EPS: $3.12 versus $2.00 Adjusted EPS: $4.18 versus $3.50 Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timing ...

Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C. , Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzh...

CHICAGO--(BUSINESS WIRE)--A streamlined digital experience improved lab order adherence, reduced no-shows, and enhanced operational efficiency at Providence.